MTOR and acute myeloid leukemia: This discovery is consistent with human studies, where patients with acute myeloid leukaemia (AML) show reduced sesn expression and increased mTOR levels in peripheral blood and bone marrow [49], and T2A treatment reduces PI3K activity and increases sesn expression in related human osteosarcoma cells [4].